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ABSTRACT: The population undergoing dialysis is aging worldwide, particularly in Japan.  The clinical 
condition of frailty is the most problematic expression in the elderly population. Potential pathophysiological 
factors of frailty present in patients with CKD and are accentuated in patients with ESRD.  The aim of this study 
was to identify the prevalence and predictors of frailty in Japanese HD patients. This study was a multicenter, 
cross-sectional and observational investigation conducted at 6 institutions.  To evaluate frailty, the modified 
Fried’s frailty phenotype adjusted for Japanese as the self-reported questionnaire was used. Of the 542 patients 
visiting each institution, 388 were enrolled in this study.  In total, 26.0% of participants were categorized as not-
frailty, 52.6% as pre-frailty and 21.4% as frailty.  The prevalence of frailty increased steadily with age and was 
more prevalent in females than in males and the subjects with frailty received polypharmacy.  A multivariate 
logistic regression analysis revealed that the factors independently associated with frailty were the following: 
female gender (odds ratio [OR] = 3.661, 95% confidence interval [CI] 1.398-9.588), age (OR = 1.065, 95% CI 
1.014-1.119), age ≥ 75 years old (OR = 4.892, 95% CI 1.715-13.955), body mass index (BMI) < 18.5 (OR = 0.110, 
95% CI 0.0293-0.416), number of medications being taken (OR = 1.351, 95% CI 1.163-1.570), diabetes mellitus 
(DM) (OR = 2.765, 95% CI 1.081-7.071) and MNA-SF ≤ 11 (OR = 7.405, 95% CI 2.732-20.072).  Frailty was 
associated with the accumulation of risk factors. The prevalence of frailty in Japanese patients with HD was 
relatively lower than that previously reported in Western developed countries; however, it was extremely high 
compared to the general population regardless of age.  Our findings suggest that frailty might be associated with 
an increase in the prevalence of adverse health outcomes in patients with HD. 
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Recently, the lifespan of the global population has begun 
rapidly increasing. Globally, life expectancy at birth 
increased from 61.7 years in 1980 to 71.8 years in 2015 
[1].  However, by contrast, the healthy life expectancy at 
birth was 60.9 years for men and 64.9 years for women in 
2015.  The gap between life expectancy and healthy life 
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expectancy represents years of functional health lost [2].  
This gap has thus become a major concern worldwide.  
A particularly problematic issue plaguing the elderly 
population is the clinical condition of frailty.  Frailty is 
considered to indicate the end of healthy life expectancy 
and develops as a consequence of the age-related decline 
in physiological systems, resulting in increasing 
individual vulnerability to health status changes [3].  Fried 
et al. developed a frailty phenotype as a convenient 
definition of frailty [4].  Frailty leads to social endpoints, 
such as hospitalization, fall and worsening activity of 
daily life (ADL), as well as hard endpoints, such as 
mortality.  This report brought frailty global focus.  The 
factors associated with presence of frailty were aging, 
female gender, race, socioeconomic state [3], smoking, 
obesity, shrinking, a history of cardiovascular disease 
(CVD), bone fracture, falling, chronic obstructive 
pulmonary disease, diabetes mellitus (DM), depression 
[5], undernutrition [6], dementia [7], malignancy [8], 
chronic kidney disease (CKD) and end-stage renal disease 
(ESRD) [9]. 
The ESRD population is also aging worldwide, 
particularly in Japan. The mean age of the total Japanese 
ESRD population is 67.2 years, and 61.8% were ≥ 65 
years old, and 30.3% were ≥ 75 years old at the end of 
2013 [10].  Potential pathophysiological factors of frailty 
present in patients with CKD, and even more are found in 
patients with ESRD [11].  According to Fried’s definition, 
the frailty status has been documented in 7% of the elderly 
population, 14% of CKD patients without dialysis and 
42% of adult ESRD patients on hemodialysis (HD) [9].  
The prevalence of frailty among the Japanese elderly and 
CKD population is comparable to the above-mentioned 
values [12-14].  However, the status of frailty among 
Japanese HD patients remains unknown.  
The aim of this study was to identify the prevalence 
and predictors of frailty in Japanese HD patients. 
 
MATERIALS AND METHODS 
 
Study Design and participants 
 
This study was a multicenter, cross-sectional and 
observational investigation, which started on October 
2015.  This study was conducted at 6 institutions with an 
HD unit, including 5 general hospitals and 1 private clinic: 
Innoshima General Hospital, Nippon Kokan Fukuyama 
Hospital, Sumitomo Besshi Hospital, Mihara Shiromachi 
Hospital, Akaiwa Medical Association Hospital and 
Sugimoto Clinic.  All of the data were obtained by the 
attending physicians and medical staff at each institution 
and sent to the Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences for the 
analysis. The patient recruitment ended in January 2016. 
The subjects were all chronic hemodialysis patients 
who regularly visited the institutions within the period of 
this study, and who agreed with the aim and protocol of 
the present study.  The initial exclusion criteria were: (1) 
refusal to participate, (2) hospitalization due to accidents 
or sickness, (3) patients who found it difficult to answer 
the questionnaire due to severe dementia or 
communication disability and (4) temporary hemodialysis 
patients or patients who had received hemodialysis for 
less than 3 months. Finally, we excluded participants who 
did not completely fill in the frailty contents (which we 
explain below “Definition of the frailty phenotype” 
paragraph) in the questionnaire completely, from those 
remaining after the initial exclusion, because the presence 
or absence of frailty could not be properly assessed.   
 
 
Table 1. Operational definition of the frailty phenotype in the present study 
 
Criteria  Definition 
   
Weight Loss  Unintentional weight loss ≥ 2 kg in the previous year 
Poor Endurance  Positive answer to a self-reported question, about how the participant had felt in the last 
2 weeks: “Did you feel exhausted without any reason?” 
Weakness  Grip strength by gender 
Males: < 26.0 kg, Females: < 18.0 kg 
Slowness  Positive answer to either of two self-reported questions, if participants were asked about 
their walking speed: “Are you unable to walk at a pace of ≥ 1.0 m/sec?”, “Is it hard for 
you to cross over a crosswalk within the time allotted?” 
Low activity  Negative answer to both of two self-reported questions, on the participants’ activity: “Do 
you lightly exercise or work at least once a week?”, “Do you regularly play any sports at 
least once a week?” 
   
 
Frail: ≥ 3 criteria met 
Intermediate or Pre-Frail: 1 or 2 criteria met 
Not frail: no criteria met 
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Evaluation measurements and factors 
 
By checking medical records, the following risk factors of 
each patient were evaluated: body mass index (BMI), 
hypertension (HTN), dyslipidemia (DLP), DM, smoking 
habit (SMK), ischemic heart disease (IHD), stroke (STK), 
peripheral arterial disease (PAD), malignancy (MLG), 
frequency and quantity of dialysis, data of blood tests, 
ankle-brachial index (ABI), brachial-ankle plus wave 
velocity (baPWV), history of bone fracture (BF) and 
ESRD.  The definition of HTN, DLP, DM, IHD, STK and 
PAD, and measurement of physical domain are described 
in supplement file.  To evaluate the dialysis efficiency, we 
calculated single-pooled Kt/V (spKt/V) [15]. To evaluate 
the nutritional status, we calculated normalized protein 
catabolic rate (nPCR) [16] and Geriatric Nutritional Risk 
Index (GNRI) [17], and asked participants to fill out the 
Mini Nutritional Assessment-Short Form (MNA-SF) [18] 
questionnaire.  To evaluate the frailty status, we asked 
participants to check the appropriate boxes no the frailty 
phenotype questionnaire which we made according to the 
“Definition of the frailty phenotype” described below. 
 
Definition of the frailty phenotype 
 
The operational definition of frailty phenotype in the 
present study was as follows (see details in Table 1):  All 
five criteria were modified from the original Fried CHS 
frailty phenotype [4], for Japanese population.  Weight 
loss was defined as unintentional weight loss ≥ 2 kg in the 
previous year, according to an indicator of nutrition for 
identifying vulnerable older adults in the long-term care 
insurance system on the Kihon-Checklist, which is a self-
reported comprehensive health checklist developed by the 
Japan Ministry of Health, Labour and Welfare [19].  Poor 
Endurance was defined by a positive answer to a self-
reported question, about how the participant had felt in the 
last 2 weeks: “Did you feel exhausted without any reason?” 
which is also taken from the Kihon-Checklist [19].   
Weakness was defined using the maximum grip strength 
by gender according to the Asian Working Group for 
Sarcopenia criteria (Males: < 26.0 kg, Females: < 18.0 kg) 
[20].  Slowness was defined by a positive answer to either 
of two self-reported questions, if participants were asked 
about their walking speed: “Are you unable to walk at a 
pace of ≥ 1.0 m/sec?”, “Is it hard for you to cross over a 
crosswalk within the time allotted?”, according to a 
previously established cut-off of walking speed <1.0 m/s 
[14].  Low activity was defined as negative answer to both 
of two self-reported questions, on the participants’ 
activity: “Do you lightly exercise or work at least once a 
week?”, “Do you regularly play any sports at least once a 
week?”, which was also taken from the same established 
definition [14]. Individuals who met at least 3 criteria 
were defined as frailty.  Individuals who met 1 or 2 criteria 
were defined as pre-frailty (intermediate frailty status), 
and those not meeting any criteria were considered as not-
frailty.   
 
Ethics 
 
This study complied with the Declaration of Helsinki 
(seventh revision, 2013) on medical protocol and ethics.  
This was a cross-sectional observational study.  Since we 
collected the data from physicians’ charts and 
questionnaires filled out by the patients, the Institutional 
Review Boards at each hospital waived the requirement 
of written informed consent but requested patients be 
given the opportunity to refuse enrollment in this study by 
leaflets or the hospital website.  Finally, each ethics 
committee of the Institutional Review Board approved the 
protocol (UMIN ID: 000024783).  
 
 
Figure 1. Diagram of participants enrolled in this study. 
 
 
Statistical analysis 
 
All data were expressed as the mean ± standard deviation 
or n (%).  Differences among each phenotype were 
examined by a one-way analysis of variance or chi-
squared test.  To evaluate the predictors of frailty and pre-
frailty, we performed univariate and multivariate logistic 
regression analyses which estimated the prevalence odds 
ratio (OR) for frailty relative to not-frailty and for pre-
frailty relative to not-frailty.  Regarding explanatory 
variables, we assessed all of the evaluated risk factors for 
frailty that are described in above “Evaluation 
measurements and factors”.  Parameters such as age and 
the laboratory data were evaluated with both continuous 
variables and binary variables with known specific cut-off 
values.  For the multivariate logistic regression analysis, 
we simultaneously introduced independent variables into 
the several models based on classical risk factors for 
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frailty, such as age, female gender, DM, IHD, STK, PAD, 
BF, Fall, obesity (BMI ≥ 25.0) or underweight (BMI < 
18.5) and MLG. Factors which had strong confounding 
influence on each other were not included in the same 
model. 
A difference of P < 0.05 was taken as statistically 
significant.  All data were analyzed using Sigma Plot for 
Windows (version 13.0, Systat Software Inc., San Jose, 
California, USA). 
 
 
 
 
Figure 2. Number of frailty criteria present; Prevalence of 
Frailty status 
 
RESULTS 
 
Study Participants 
 
As shown in Figure 1, among the 542 patients visiting 
each institution, 129 did not participate due to refusal and 
hospitalization due to sickness or difficulty in 
communication, 25 patients who were unable to properly 
fill out the frailty questionnaire were excluded.  Finally, 
388 patients were enrolled in this study.  The baseline 
characteristics of the participants are displayed in 
Supplemental Table 1.  Participants were an average of 
67.2 ± 11.9 years old with more male gender (62.4%) than 
female.  Almost all patients received HD for 4 hours in 3 
sessions a week.  The leading etiology of ESRD was 
diabetic nephropathy.  Those characteristics were similar 
to the population of typical chronic HD patients in Japan.   
 
Frailty Prevalence among Dialysis patients 
 
The total frailty criteria score and prevalence of each 
frailty phenotype are shown in Figure 2.  In total, 21.4% 
of participants were categorized as frailty, 52.6% as pre-
frailty and 26.0% as the subjects without frailty.  
 
 
 
 
 
 
 
Figure 3. The Ratio of the Frailty Phenotypes according to the Duration of Dialysis and Age. The upper panel 
shows the ratio of the frailty phenotypes according to the duration of dialysis. The lower panel shows the ratio of 
the frailty phenotypes according to the age. 
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Table 2. Characteristics of each frailty phenotype 
 
 
Variable 
Not frail 
(n = 101) 
Pre-Frail 
(n = 204) 
Frail 
(n = 83) 
 
P value 
     
Age, (years) 63.6  11.2 67.5  12.3 71.0  10.2 < 0.001** 
Gender (male), n (%) 70 (69.3 %) 135 (66.2 %) 37 (44.6 %) < 0.001** 
Height, (cm) 162.0  8.9 159.7  9.3 155.2  9.0 < 0.001** 
Weight, (kg) 56.0  11.1 56.6  12.1 52.9  10.4 0.043* 
Body mass index, (kg/m²) 21.2  3.4 22.1  3.5 21.9  3.8 0.155 
Brachial circumference, (cm) 25.3  3.1 25.3  3.2 24.8  2.9 0.481 
Rt. Femoral circumference, (cm) 42.4  5.4 41.5  5.2 40.0  5.0 0.007** 
Lt. Femoral circumference (cm) 42.5  5.1 41.0  5.1 39.8  4.8 0.006** 
Grip strength, (kg) 26.5  9.7 22.1  11.1 15.8  7.5 < 0.001** 
Rt. ABI 1.13  0.19 1.12  0.23 1.07  0.26 0.123 
Lt. ABI 1.11  0.17 1.10  0.23 1.07  0.24 0.485 
     
Hb, (g/dL) 10.8  1.0 10.8  1.0 10.7  1.0 0.517 
Alb, (g/dL) 3.7  0.8 3.6  0.3 3.5  0.4 0.003** 
T-Chol, (mg/dL) 163  40 159  41 154  40 0.363 
UN, (mg/dL) 63.7  14.3 63.2  17.3 60.2  20.1 0.338 
Cr, (mg/dL) 10.76  5.13 9.44  2.41 8.35  2.17 <0.001** 
     
Number of oral medications 9.3  3.2 9.9  3.7 12.1  3.8 < 0.001** 
Dementia drugs used, n (%) 0 (0.0 %) 5 (2.5 %) 3 (3.6 %) 0.195 
Smoker (current + former), n (%) 54 (53.5 %) 89 (43.6 %) 30 (36.1 %) 0.058 
History of falling, n (%) 15 (14.9 %) 52 (25.5 %) 30 (36.1 %) 0.004** 
     
Dialysis frequency, (sessions/week) 3.0  0.1 3.0  0.2 3.0  0.3 0.328 
Dialysis time, (hour/session) 4.1  0.3 4.1  0.3 4.1  0.4 0.559 
Duration of dialysis, (years) 8.6  7.3 8.3  7.4 9.5  8.4 0.431 
spKt/V urea 1.48  0.37 1.46  0.39 1.50  0.40 0.744 
nPCR, (g/kg/day) 0.87  0.12 0.87  0.16 0.84  0.20 0.336 
GNRI 95.3  14.2 95.6  8.6 93.5  10.1 0.313 
MNA-SF 11.9  2.1 11.7  1.8 10.2  2.6 <0.001** 
     
Etiology of ESRD     
CGN, n (%) 47 (46.5 %) 50 (24.5 %) 20 (24.1 %) < 0.001** 
DN, n (%) 24 (23.8 %) 75 (36.8 %) 39 (47.0 %) 0.004** 
NS, n (%) 9 (8.9 %) 17 (8.3 %) 1 (1.2 %) 0.066 
PKD, n (%) 2 (2.0 %) 8 (3.9 %) 3 (3.6 %) 0.667 
Others, n (%) 7 (6.9 %) 22 (10.8 %) 8 (9.6 %) 0.559 
Unknown, n (%) 12 (11.9 %) 32 (15.7 %) 12 (14.5 %) 0.673 
     
HTN, n (%) 76 (75.2 %) 151 (74.0 %) 60 (72.3 %) 0.901 
DLP, n (%) 16 (15.8 %) 47 (23.0 %) 20 (24.1 %) 0.281 
DM, n (%) 26 (25.7 %) 89 (43.6 %) 47 (56.6 %) < 0.001** 
IHD, n (%) 21 (20.8 %) 48 (23.5 %) 20 (24.1 %) 0.833 
STK, n (%) 8 (7.9 %) 27 (13.2 %) 19 (22.9 %) 0.013* 
PAD, n (%) 13 (14.0 %) 29 (16.5 %) 21 (28.4 %) 0.038* 
MLG, n (%) 7 (6.9 %) 20 (9.8 %) 8 (9.6 %) 0.695 
BF, n (%) 5 (5.0 %) 22 (10.8 %) 11 (13.3 %) 0.133 
     
 
The data are presented as the mean value ± standard deviation or n (%) of patients. Hb, hemoglobin; Alb, albumin; T-Chol, total 
cholesterol; UN, urea nitrogen; Cr, creatinine; spKt/V urea, dialysis efficacy; nPCR, normalized protein catabolic rate; GNRI, 
Geriatric Nutritional Risk Index; MNA-SF, mini nutritional assessment-short form; ESRD, end-stage renal disease; CGN, chronic 
glomerulonephritis; DN, diabetic nephropathy; NS, nephrosclerosis; PKD, polycystic kidney disease; HTN, hypertension; DLP, 
dyslipidemia; DM, diabetes mellitus; IHD, ischemic heart disease; STK, stroke; MLG, malignancy; BF, bone fracture. P values 
are obtained by One Way ANOVA test or chi-square test. *P < 0.05, **P < 0.01. 
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Table 3. Univariate predictors of frail and pre-frail. 
 
  Pre-Frail    Frail  
 Odds ratio 95% CI P value  Odds ratio 95% CI P value 
        
Female 1.154 0.691-1.927 0.584  2.807 1.533-5.141 < 0.001** 
Age, years 1.027 1.007-1.048 0.009**  1.072 1.037-1.107 < 0.001** 
Age ≥ 65 y.o. 1.273 0.784-2.067 0.329  2.788 1.450-5.359 0.002** 
Age ≥ 75 y.o. 3.390 1.733-6.635 < 0.001**  5.966 2.840-12.529 < 0.001** 
BMI ≥ 25.0 2.121 1.041-4.324 0.038*  1.660 0.710-3.883 0.242 
BMI <18.5 0.654 0.361-1.188 0.163  0.412 0.179-0.949 0.037* 
DN 1.865 1.088-3.199 0.023*  2.844 1.516-5.335 0.001** 
HTN 0.974 0.561-1.692 0.925  0.858 0.444-1.660 0.649 
DLP 1.632 0.872-3.053 0.125  1.687 0.810-3.513 0.163 
DM 2.272 1.343-3.842 0.002**  3.776 2.021-7.018 < 0.001** 
IHD 1.195 0.669-2.134 0.547  1.209 0.603-2.425 0.592 
STK 1.783 0.779-4.082 0.171  3.451 1.424-8.364 0.006** 
PAD 1.214 0.598-2.466 0.592  2.438 1.125-5.287 0.024* 
MLG 1.468 0.599-3.595 0.401  1.432 0.497-4.129 0.506 
BF 2.334 0.857-6.357 0.097  2.933 0.976-8.816 0.055 
Fall 1.991 1.057-3.751 0.033*  3.208 1.580-6.514 0.001** 
Smoking 0.680 0.419-1.105 0.119  0.472 0.260-0.857 0.014* 
NOM 1.044 0.974-1.119 0.221  1.256 1.140-1.383 < 0.001** 
Hypo-Alb 1.305 0.754-2.261 0.341  1.913 1.010-3.622 0.047* 
Hypo-Chol 1.086 0.671-1.758 0.736  1.382 0.771-2.477 0.278 
spKt/V ≥1.80 0.844 0.464-1.535 0.578  1.290 0.647-2.572 0.469 
spKt/V <0.80 3.553 0.431-29.281 0.239  1.220 0.075-19.798 0.889 
nPCR <0.90 1.018 0.629-1.646 0.944  1.230 0.681-2.223 0.492 
GNRI ≤91 0.901 0.542-1.497 0.687  1.509 0.829-2.747 0.178 
MNA-SF ≤11 1.316 0.804-2.154 0.275  3.958 2.135-7.338 < 0.001** 
        
 
CI, confidence interval; BMI, body mass index; DN, diabetic nephropathy; HTN, hypertension; DLP, dyslipidemia; DM, diabetes mellitus; 
IHD, ischemic heart disease; STK, stroke; PAD, peripheral arterial disease; MLG, malignancy; BF, bone fracture; NOM, number of oral 
medicine; Hypo-Alb, hypoalbuminemia; Hypo-Chol, hypocholesterolemia; spKt/V, dialysis efficacy; nPCR, normalized protein catabolic 
rate; GNRI, geriatric nutritional risk index; MNA-SF, mini nutritional assessment-short form. The odds ratio and P values were obtained by 
a univariate logistic regression analysis. *P < 0.05, **P < 0.01. 
In Supplemental Figure 1, the population and 
prevalence of each frailty criterion are shown.  In this 
study, the prevalence of each criterion was all 
significantly higher in the frailty group than that in the 
pre-frailty group.  Among the subjects with frailty, the 
prevalence of “Poor Endurance”, “Slowness” and “Low 
Activity” were higher than that of “Weakness” and 
“Weight Loss”.  In contrast, among the subjects with pre-
frailty, “Low Activity” had the highest prevalence.  
There was no relationship between the duration of HD 
and frailty status as shown in Figure 3.  On the other hand, 
the number of subjects with frailty increased steadily with 
age (Figure 3 and Supplemental Figure 2).  Among the 
elderly subjects, the population ≥ 75 years old had the 
highest prevalence of frailty (Figure 3).  Furthermore, 
13.5% of non-elderly patients were frailty, despite the fact 
that frailty is a geriatric syndrome. 
In Table 2, the characteristics of each frailty 
phenotype are shown.  The average age of subjects 
increased significantly as the frailty stages progressed, 
and frailty was more prevalent in females than in males.  
The subjects with frailty or pre-frailty had lower body 
weight and lower grip strength than those without frailty.  
Serum albumin concentrations were slightly lower in the 
subjects with frailty and pre-frailty than in those without 
frailty.  The subjects with frailty were under the treatment 
of polypharmacy: the mean number of tablets 
administered to the patients with frailty, pre-frailty and 
those without frailty were 12.1, 9.9 and 9.3 respectively.  
There was no marked difference in the frequency or 
efficiency of hemodialysis among each phenotype. 
 
Nutritional Status  
 
There was unexpectedly no marked difference in nPCR or 
GNRI according to the frailty status.  Only MNA-SF 
differed significantly between subjects with frailty and 
others.  The prevalence of patients according to MNA-SF 
scores are shown in Figure 4.  The subjects with frailty 
increased as malnutrition developed.  The details of the 
factors which comprise MNA-SF are shown in Figure 5 
(A)-(F).  The scores tended to be lower for the subjects 
with frailty or pre-frailty in each category except for BMI. 
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Figure 4. The Ratio of Frailty Phenotypes according to the MNA-SF Score. P value was obtained by chi-square test. 
 
Accumulation of the Risk Factors for Frailty 
 
When comparing the number of risk factors for frailty, 
patients with frailty appeared to have more risk factors 
than others.  Figure 6 shows the prevalence of each frailty 
status, according to the number of cardiovascular diseases 
(IHD, STK and / or PAD).  The proportion of frailty 
steadily increased as the number of cardiovascular disease 
increased, with borderline significance. In addition, the 
prevalence of frailty according to the number of general 
risk factors for frailty (cardiovascular diseases, MLG, 
obesity, BF, hypoalbuminemia and/or DM), is also shown 
in Figure 6.  The proportion of patients with frailty 
significantly increased as the number of risk factors 
increased. These results imply that the accumulation of 
risk factors easily leads patients to frailty. 
 
 
Table 4. Multivariate Analysis of predictors for frail and pre-frail 
 
  Pre-Frail    Frail  
 Odds ratio 95% CI P value  Odds ratio 95% CI P value 
Female 1.380 0.759-2.509 0.292  3.661 1.398-9.588 0.008** 
Age 1.026 1.004-1.049 0.019*  1.065 1.014-1.119 0.013* 
BMI ≥ 25.0 2.463 1.079-5.623 0.032*     
BMI <18.5     0.110 0.0293-0.416 0.001** 
NOM 1.038 0.954-1.130 0.383  1.351 1.163-1.570 < 0.001** 
DM 2.274 1.203-4.296 0.011*  2.765 1.081-7.071 0.034* 
IHD 0.882 0.414-1.877 0.744  1.026 0.331-3.181 0.964 
STK 1.383 0.524-3.653 0.513  3.136 0.824-11.929 0.094 
PAD 0.775 0.337-1.783 0.548  2.314 0.730-7.332 0.154 
MLG 1.382 0.517-3.692 0.519  0.877 0.170-4.535 0.876 
BF 1.612 0.469-5.541 0.449  1.415 0.247-8.097 0.696 
Fall 1.176 0.559-2.473 0.670  1.526 0.468-4.978 0.483 
MNA-SF ≤11 1.448 0.817-2.567 0.205  7.405 2.732-20.072 < 0.001** 
 
CI, confidence interval; BMI, body mass index ; NOM, number of oral medicine; DM, diabetes mellitus; IHD, ischemic heart disease; 
STK, stroke; PAD, peripheral arterial disease; MLG, malignancy; BF, bone fracture; Hypo-Alb, hypoalbuminemia; MNA-SF, mini 
nutritional assessment-short form. The above data were adjusted for all items written in the column. The odds ratio and P values were 
obtained by a multivariate logistic regression analysis. *P < 0.05, **P < 0.01. 
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Table 5. Multivariate Analysis of predictors for frail and pre-frail, categorized as elderly criteria 
 
 Pre-Frail  Frail Model 1  Frail Model 2 
 
Odds 
ratio 
95% CI P value 
 Odds 
ratio 
95% CI P value 
 Odds 
ratio 
95% CI P value 
            
Female 
1.650 0.889-3.064 0.113  
3.581 1.395-9.190 0.008** 
 
3.733 
1.413-
9.858 
0.008** 
Age ≥ 65 y.o.     2.429 0.894-6.599 0.082     
Age ≥ 75 y.o. 
3.928 1.827-8.447 <0.001**  
   
 
4.892 
1.715-
13.955 
0.003** 
BMI ≥ 25.0 2.731 1.196-6.328 0.017*         
BMI <18.5 
    
0.104 0.0281-0.383 < 0.001** 
 
0.129 
0.0335-
0.499 
0.003** 
NOM 
1.035 0.949-1.130 0.433  
1.344 1.161-1.556 < 0.001** 
 
1.389 
1.192-
1.618 
<0.001** 
DM 
2.704 1.400-5.226 0.003**  
2.864 1.125-7.294 0.027* 
 
2.811 
1.069-
7.387 
0.036* 
IHD 
0.886 0.410-1.916 0.758  
1.076 0.355-3.259 0.897 
 
0.929 
0.293-
2.950 
0.901 
STK 
1.260 0.467-3.403 0.648  
3.392 0.921-12.493 0.066 
 
3.414 
0.921-
12.658 
0.066 
PAD 
0.687 0.292-1.619 0.391  
2.176 0.681-6.946 0.189 
 
2.613 
0.805-
8.481 
0.110 
MLG 
1.450 0.528-3.979 0.471  
0.916 0.175-4.788 0.917 
 
0.910 
0.174-
4.763 
0.911 
BF 
1.662 0.464-5.948 0.435  
1.660 0.297-9.296 0.564 
 
1.368 
0.226-
8.296 
0.733 
Fall 
1.180 0.551-2.529 0.670  
1.598 0.483-5.285 0.443 
 
1.653 
0.505-
5.409 
0.406 
Hypo-Alb 
1.202 0.618-2.339 0.588  
1.884 0.684-5.189 0.221 
 
1.732 
0.617-
4.858 
0.297 
MNA-SF ≤11 
1.529 0.884-2.866 0.121  
7.207 2.702-19.221 < 0.001** 
 
7.609 
2.742-
21.115 
<0.001** 
            
 
CI, confidence interval; y.o., years old; BMI, body mass index; NOM, number of oral medicine; DM, diabetes mellitus; IHD, ischemic heart disease; 
STK, stroke; PAD, peripheral arterial disease; MLG, malignancy; BF, bone fracture; Hypo-Alb, hypoalbuminemia; MNA-SF, mini nutritional 
assessment-short form. The above three models were adjusted for all items written in the column. The odds ratio and P values were obtained by a 
multivariate logistic regression analysis. *P < 0.05, **P < 0.01 
Predictors of Frailty 
 
The predictors of frailty and pre-frailty evaluated by 
univariate and multivariate logistic regression analysis, 
are shown in Table 3, 4 and 5.  The factors independently 
associated with frailty were the following: female gender 
(OR = 3.661, 95% CI 1.398-9.588), age (OR = 1.065, 95% 
CI 1.014-1.119), age ≥ 75 years old (OR = 4.892, 95% CI 
1.715-13.955), BMI < 18.5 (OR = 0.110, 95% CI 0.0293-
0.416), number of medications being taken (OR = 1.351, 
95% CI 1.163-1.570), DM (OR = 2.765, 95% CI 1.081-
7.071) and MNA-SF ≤ 11 (OR = 7.405, 95% CI 2.732-
20.072).  There were no significant relationships among 
obesity (BMI ≥ 25.0), efficiency of hemodialysis, nPCR 
and GNRI, in any combination of multivariate regression 
model (data not shown). 
 
Association between physical domain and Frailty 
 
The physical relationships with frailty are shown 
Supplemental Table 2 and 3.  The physical domains 
significantly associated with frailty were height, weight, 
femoral circumference and grip strength.  However, after 
adjustment for age and sex, only grip strength retained a 
significant independent association with frailty.  In 
addition, there was a significant negative correlation 
between grip strength and the frailty phenotype score.  
These findings suggest that bodily functions might 
contribute to frailty in respects other than the physical 
constitution or muscle mass.  
 
DISCUSSION 
 
To our knowledge, this is the first investigation 
concerning the prevalence of frailty among Japanese 
prevalent patients with chronic HD.  This study 
demonstrated that the proportion of patients meeting the 
self-reported functional-based definition of frailty, was 
markedly higher than that of the community-dwelling 
elderly population [13, 14]: approximately 3 to 4 folds 
higher.  In contrast, the prevalence of frailty with HD 
patients in this study was relatively lower than that noted 
in previous studies in other developed countries: 21.4% in 
this study vs around 42-73% in other developed countries 
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[9, 21-25], despite that Japanese dialysis population are 
older compared with other developed countries [26].  In 
addition, the proportion of HD patients with frailty was 
higher among non-elderly individuals than among those 
in the community-dwelling population. Predictors of 
frailty were almost the same as previously reported [3, 21, 
27].  Age (especially 75 years old and above), female 
gender, the number of medicine, DM and MNA-SF ≤ 11 
(at risk of malnutrition) were independently and 
significantly associated with frailty.  Furthermore, the 
accumulation of risk factors for frailty was observed in 
frail patients.  These risk factors are generally related to 
disability, mortality and several complications.  Therefore, 
this indicates that the patients with frailty might be 
associated with an increased prevalence of adverse health 
outcomes in patients with HD.  Although we have not yet 
performed a further longitudinal investigation, these 
findings suggest that frailty might affect the prognosis and 
quality of life (QOL) of patients with HD. 
 
 
 
 
 
Figure 5. Details of MNA-SF Score. Panel (A) shows the proportion of MNA-SF criteria A: “Has food intake declined over the past 
3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties?” in each frailty status. Panel (B) shows the 
proportion of MNA-SF criteria B: Weight loss during the last 3 months, in each frailty status. Panel (C) shows the proportion of MNA-
SF criteria C: Mobility, in each frailty status. Panel (D) shows the proportion of MNA-SF criteria D: “Has suffered psychological stress 
or acute disease in the past 3 months?” in each frailty status. Panel (E) shows the proportion of MNA-SF criteria E: Neuropsychological 
problems, in each frailty status. (F) shows the proportion of MNA-SF criteria F1: Body Mass Index or F2: Calf circumference, in each 
frailty status. P values were obtained by chi-square tests. 
 
CKD and Dialysis 
 
CKD patients easily develop “Protein Energy 
Wasting (PEW)”, accompanied by malnutrition and a 
reduction in the muscle mass [28].  Loss of muscle mass, 
as investigated by the biological impedance method, was 
frequently observed with a reduced eGFR or albuminuria-
positive patients [29].  Dialysis patients might age 15 
years faster than healthy people, observed in the 
Gompertz equation model [30].  Several reports are 
available concerning that toxic factors in uremic state 
accelerated aging and led to a progressively impaired 
organ function [31].  In addition, anorexia caused by 
uremic toxins, dialysate and urine nutrient losses, 
catabolic effect, chronic low-grade inflammation, 
deficiency or resistance to anabolic hormone and physical 
inactivity have been reported to induce PEW and frailty 
[11].  Furthermore, the physical activity is known to 
decrease in HD patients, due to the maintenance of HD 
and fatigue after HD, leading to physical deconditioning.     
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Figure 6. Prevalence of Frailty Phenotypes according to the Number of Cardiovascular Disease and the Number of General 
Risk Factors. The upper panel shows the prevalence of frailty phenotypes according to the number of the cardiovascular disease. 
The lower panel shows the prevalence of frailty phenotypes according to the number of the general risk factors for frailty. 
Cardiovascular diseases are ischemic heart disease, stroke and peripheral artery disease. The general risk factors for frailty are 
ischemic heart disease, stroke, peripheral artery disease, malignancy, obesity, bone fracture, hypoalbuminemia and/or diabetes. P 
value were obtained by chi-square tests. 
 
Accordingly, these findings indicate that CKD and 
ESRD patients are particularly susceptible to frailty.  
Indeed, the prevalence of frailty increased as CKD stage 
progressed [32].  In analyses using data from the US Renal 
Data System (USRDS), 67.7% of the 2275 dialysis 
patients were considered as frailty [21].  Furthermore, in 
the population undergoing HD, there were a substantial 
number of patients with frailty in the non-elderly group, 
and frailty is a strong and independent predictor of 
mortality and hospitalizations, regardless of age [21, 24].  
In our findings, muscular strength and muscle mass 
decreased and the accumulation of risk factors for frailty 
including cardiovascular disease was observed in patients 
with frailty. These factors are generally related to 
disability, mortality and other complications.  Thus, it is 
important to detect frailty and intervene at an early stage, 
before it progresses to disability and leads to adverse 
health outcomes. 
 
Comparison with other countries 
 
The prevalence of frailty in the present study was almost 
half of that noted in other developed countries.  Two 
studies using the CHS frailty phenotype model, in which 
the definition of frailty is almost the same as our own, 
estimated the prevalence of frailty in the community-
dwelling elderly population in Japan to be 6.9% and 9.3%, 
respectively [13, 14].  When restricted to the reports using 
the CHS frailty phenotype model, the average prevalence 
of frailty was 9.9% (95% CI: 9.6-10.2%) [33].  These 
results suggest that the characteristic background of the 
general population may not differ markedly between 
Japanese and Western population.   
The increased longevity of Japanese HD patients in 
comparison to HD patients in other developed countries 
may be one of the reasons for the discrepancy in the 
prevalence of frailty in the present study and other studies 
on frailty in patients HD [34].  Recently, it was reported 
that the health-related quality life (HR-QOL) was 
associated with mortality in HD patients, and DOPPS 
investigators found a higher physical component score of 
HR-QOL among Japanese patients with HD than that 
among participants from other countries [35].  Indeed, it 
was reported that the status of frailty was closely 
associated with HR-QOL [36].  These factors may 
underlie the differences in the prevalence of frailty by 
country.  
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Supplemental Table 1. The baseline characteristics of all participants. 
 
Variable Completely filled 
(n = 388) 
Incompletely filled 
(n = 25) 
P-Value 
    
Age, (years) 67.2  11.9 71.9  11.2 0.054 
Gender (male), n (%) 242 (62.4 %) 14 (56.0 %) 0.672 
Height, (cm) 159.4  9.4 158.9  9.4 0.817 
Weight, (kg) 55.7  11.5 54.3  11.3 0.561 
Body mass index, (kg/m²) 21.8  3.5 21.3  3.4 0.483 
    
Hb, (g/dL) 10.8  1.0 10.9  1.0 0.587 
Alb, (g/dL) 3.6  0.5 3.6  0.3 0.845 
T-Chol, (mg/dL) 159  41 159  41 0.979 
UN, (mg/dL) 62.7  17.2 68.2  16.1 0.117 
Cr, (mg/dL) 9.55  3.39 8.48  1.81 0.119 
    
Number of medications 10.2  3.7 10.2  4.1 0.941 
    
Dialysis frequency, (sessions/week) 3.0  0.2 3.0  0.0 0.944 
Dialysis time, (hours/session) 4.1  0.4 4.1  0.6 0.655 
Duration of dialysis, (years) 8.7  7.6 5.5  6.0 0.036 
spKt/V urea 1.29  0.34 1.30  0.43 0.487 
nPCR, (g/kg/day) 0.87  0.16 0.89  0.17 0.417 
    
GNRI 95.2  10.3 94.5  8.2 0.766 
MNA-SF 11.5  2.2 10.4  2.6 0.017 
    
Brachial circumference, (cm) 25.2  3.1 25.3  3.9 0.918 
Rt. Femoral circumference, (cm) 41.4  5.3 42.0  5.4 0.624 
Lt. Femoral circumference (cm) 41.1  5.1 42.3  4.9 0.314 
Grip strength, (kg) 22.0  10.7 23.6  9.4 0.501 
    
Blank responses in questionnaire    
0 388 (100 %) 0 (0 %)  
1 0 (0 %) 12 (85.7 %)  
2 0 (0 %) 0 (0 %)  
3 0 (0 %) 2 (14.3 %)  
    
“Yes” to frailty questionnaire    
0 101 (26.0 %) 9 (64.3 %)  
1 118 (30.4 %) 8 (57.1 %)  
2 86 (22.2 %) 6 (42.9 %)  
3 59 (15.2 %) 2 (14.3 %)  
4 19 (4.9 %) 0 (0 %)  
5 5 (1.3 %) 0 (0 %)  
    
 
The data are presented as the mean ± standard deviation or n (%) of patients. Hb, hemoglobin; Alb, albumin; T-Chol, total cholesterol; 
UN, urea nitrogen; Cr, creatinine; eKt/V, dialysis efficacy; nPCR, normalized protein catabolic rate; ESRD, end-stage renal disease; 
CGN, chronic glomerulonephritis; DN, diabetic nephropathy; NS, nephrosclerosis; PKD, polycystic kidney disease. Completely 
filled group are the participants enrolled in this study. P values were determined using the chi-squared test. 
 
The background characteristics of the 
participants in our study (including age, proportion of 
gender, etiology of ESRD, frequency and efficiency of 
hemodialysis) were almost the same as those reported by 
The Japanese Society for Dialysis Therapy at the end of 
2013.  Although we have not examined this point yet, the 
HR-QOL of the patients in the present study may be 
similar to reported Japanese population.  
 
Nutrition assessment 
 
The nPCR is valid as a measure of protein intake in HD 
patients with a neutral nitrogen balance.  Several studies 
have suggested that a poor nPCR is associated with 
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mortality [37, 38].  The GNRI has also been reported to 
be a significant predictor for mortality in HD patients [17].  
However, in the present study, no significant differences 
in the scores of these two measurements were confirmed 
among each of frailty phenotype groups.  Furthermore, 
there were only slightly differences in albumin and urea 
nitrogen levels, which used in the calculation formula as 
shown in Table 2.  Indeed, in Japan, chronic HD patients 
regularly receive nutritional counselling according to the 
guidelines of the national society of dialysis and most of 
the patients eat the lunch and / or dinner provided by their 
dialysis facilities when they visit to receive HD.  Thus, the 
difference in nutrition among the patients might be slight.  
This may be one of the reasons underlying the discrepancy 
in the prevalence of frailty between the present study and 
studies from other countries. 
In this study, the MNA-SF was the only significantly 
influential tool. In a multivariate analysis, MNA-SF ≤ 11, 
a cut-off point of “at risk of malnutrition”, also had a 
significantly higher OR than other factors.  In the several 
reports validating the MNA-SF for use in elderly subjects 
with frailty, the MNA-SF appeared to be an effective tool 
for both malnutrition and frailty screening.  One report 
showed that the 11 points cut-off, which is commonly 
considered to indicate a risk of malnutrition, provided the 
best correct classification ratio (91.4%), with a sensitivity 
= 94.0% and specificity = 83.3% [18].  Other reports also 
showed a close association between the MNA-SF and 
frailty [39-41].  Thus, in line with previous reports, we 
confirmed that MNA-SF is an influential tool in our 
research.   MNA-SF consists of 6 categories ( “declined 
food intake due to loss of appetite, digestive problem, 
chewing or swallowing difficulties”, “reduced weight 
during the last 3 months”, “Mobility”, “psychological 
stress or acute disease in the past 3 months”, 
“neuropsychological problems” and “BMI”).  In the 
clinical setting, the MNA-SF proved particularly effective 
because we are able to evaluate the risk of malnutrition 
repeatedly in a short period.  In addition, if the score of a 
component of MNA-SF is low, proper intervention should 
be provided in accordance with the category.  For example, 
if a patient has a low score for food intake, nutritional 
support, dental intervention or dysphagia rehabilitation 
should be provided.  Depending on the low score category, 
mental and physical interventions may be indicated in 
other cases.  Thus, MNA-SF is beneficial, both as a 
screening tool for frailty, and as an assessment tool for 
intervention. 
 
 
 
 
 
Supplemental Figure 1. Frequency of individual criterion 
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Supplemental Table 2. Physical Association of Frail and Pre-Frail 
 
  Pre-Frail    Frail  
 Odds ratio 95% CI P value  Odds ratio 95% CI P value 
        
Univariate Analysis        
Height, cm 1.008 0.987-1.030 0.438  0.938 0.912-0.965 <0.001** 
Weight, kg 1.016 0.998-1.034 0.084  0.972 0.949-0.994 0.015* 
BMI, kg/m² 1.042 0.984-1.103 0.158  1.011 0.945-1.082 0.784 
BC, cm 1.028 0.964-1.097 0.397  0.954 0.880-1.033 0.245 
Mean FC, cm 1.007 0.970-1.045 0.708  0.933 0.888-0.979 0.005** 
Larger FC, cm 1.004 0.966-1.043 0.851  0.931 0.886-0.978 0.004** 
Smaller FC, cm 1.007 0.968-1.048 0.727  0.927 0.881-0.976 0.004** 
Grip Strength, kg 0.963 0.941-0.986 0.002**  0.865 0.825-0.907 <0.001** 
Multivariate Analysis        
Grip Strength, kg✝ 0.964 0.935-0.993 0.016*  0.859 0.810-0.911 <0.001** 
        
 
CI, confidence interval; BMI, body mass index; BC, brachial circumference; FC, femoral circumference 
BC is the brachial circumference of dominant arm. The mean FC is the mean circumference of both femurs. A larger FC indicates a larger 
circumference for both femurs. A smaller FC indicates a smaller circumference for both femurs. The grip strength represents the grip strength 
of the dominant arm. The odds ratio and P values were obtained by a univariate logistic regression analysis. *P < 0.05, **P < 0.01. ✝, 
adjusted for age and sex. 
 
Limitations 
 
The present study is associated with several limitations.  
First, this was a cross-sectional study.  Therefore, the risk 
for hospitalization or death in the population with frailty 
was not clarified in this study.  Second, depression and 
cognitive decline were not assessed, therefore the 
influences of these factors on the findings in the current 
study could not be determined; however, the concept of 
frailty itself includes aspects of depression and cognitive 
decline in part.  Third, we did not conduct a detailed 
evaluation of the physical function, such as walking speed 
and chair standing up time.  Further, we did not check the 
exercise tolerability.  Fourth, we did not evaluate the 
subjects’ physical body composition, such as their muscle 
mass, body fat or edema, using a bioelectrical impedance 
analysis or dual energy X-ray absorptiometry; however, 
the brachial or femoral circumferences were measured, 
which we feel can be substituted as measures of the body 
composition.  Fifth, the results of a subjective evaluation 
were the primary outcome and frailty was not evaluated 
objectively.  Accordingly, the actual incidence of frailty 
might have been underestimated.  
 
Conclusion 
 
In summary, we confirmed the prevalence and predictors 
of frailty in a Japanese population with HD.  Although the 
prevalence of frailty in the present study was lower than 
that noted in previous studies in Western developed 
countries, the prevalence was still extremely high in 
comparison to the general population regardless age, and 
frailty was associated with the accumulation of risk 
factors.  The early detection and intervention are likely 
more important for preventing the adverse outcomes and 
a poor QOL in patients with HD accordingly.  Since 
patients with HD regularly visit the institution 3 times a 
week, nutritional and physical intervention are easy to 
deliver, and they can undergo repeated evaluations of their 
frailty status.  Further detailed assessments, including a 
prospective longitudinal study and interventional 
assessment will be required to improve the prognosis and 
QOL of patients with ESRD.  
 
 
Supplemental Table 3. Correlation between the frailty 
phenotype score and physical domain 
 
 Correlation 
Coefficient: r 
P value 
Height, cm -0.238 <0.001** 
Weight, kg -0.119 0.02* 
BMI, kg/m² 0.0257 0.614 
Grip Strength, kg -0.340 <0.001** 
BC, cm -0.0780 0.127 
Mean FC, cm -0.165 <0.001** 
Larger FC, cm -0.193 <0.001** 
Smaller FC, cm -0.182 <0.001** 
 
BMI, body mass index; BC, brachial circumference; FC, femoral 
circumference. BC is the brachial circumference of dominant arm. The 
mean FC is the mean circumference of both femurs. A larger FC 
indicates a larger circumference for both femurs. A smaller FC indicates 
a smaller circumference for both femurs. The grip strength represents the 
grip strength of the dominant arm. Correlation coefficient: the r and P 
values were obtained by Pearson product moment correlation. *P < 0.05, 
**P < 0.01. 
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